OBJECTIVE: To examine the effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB protein) treatment in overweight men. DESIGN: A randomized double-blind placebo-controlled trial in 24 overweight men (BMI: 28.8+/-0.3 kg/m(2); age: 34.8+/-0.9 y). PEG-OB protein (80 mg) or placebo was administered subcutaneously weekly for 6 weeks, combined with a 2.1 MJ/day energy restriction program. Dietary restraint was determined by the Three-Factor Eating Questionnaire before and after treatment, and after 8 weeks follow-up. RESULTS: During treatment dietary restraint increased, and general hunger, resting energy expenditure and respiratory quotient decreased similarly in the PEG-OB and the placebo group. With PEG-OB treatment, additional weight loss (P<0.03) was observed. During 8 weeks follow-up, body weight increase was larger in the PEG-OB group compared to placebo (P<0.05), and body weight regain was faster. Body weight regain was inversely correlated with the increase in cognitive dietary restraint during treatment (PEG-OB group: r(2)=0.49, P<0.02; placebo group: r(2)=0.60, P=0.01). CONCLUSION: Although treatment with PEG-OB protein led to a greater body weight loss relative to placebo, weight maintenance thereafter was mainly supported by dietary restraint, which was more effective in the placebo-treated group, resulting in a slower regain of body weight.
RCT Entities:
OBJECTIVE: To examine the effect of dietary restraint during and following pegylated recombinant leptin (PEG-OB protein) treatment in overweight men. DESIGN: A randomized double-blind placebo-controlled trial in 24 overweight men (BMI: 28.8+/-0.3 kg/m(2); age: 34.8+/-0.9 y). PEG-OB protein (80 mg) or placebo was administered subcutaneously weekly for 6 weeks, combined with a 2.1 MJ/day energy restriction program. Dietary restraint was determined by the Three-Factor Eating Questionnaire before and after treatment, and after 8 weeks follow-up. RESULTS: During treatment dietary restraint increased, and general hunger, resting energy expenditure and respiratory quotient decreased similarly in the PEG-OB and the placebo group. With PEG-OB treatment, additional weight loss (P<0.03) was observed. During 8 weeks follow-up, body weight increase was larger in the PEG-OB group compared to placebo (P<0.05), and body weight regain was faster. Body weight regain was inversely correlated with the increase in cognitive dietary restraint during treatment (PEG-OB group: r(2)=0.49, P<0.02; placebo group: r(2)=0.60, P=0.01). CONCLUSION: Although treatment with PEG-OB protein led to a greater body weight loss relative to placebo, weight maintenance thereafter was mainly supported by dietary restraint, which was more effective in the placebo-treated group, resulting in a slower regain of body weight.
Authors: Christos S Mantzoros; Faidon Magkos; Mary Brinkoetter; Elizabeth Sienkiewicz; Tina A Dardeno; Sang-Yong Kim; Ole-Petter R Hamnvik; Anastasia Koniaris Journal: Am J Physiol Endocrinol Metab Date: 2011-07-26 Impact factor: 4.310
Authors: Tina A Dardeno; Sharon H Chou; Hyun-Seuk Moon; John P Chamberland; Christina G Fiorenza; Christos S Mantzoros Journal: Front Neuroendocrinol Date: 2010-06-17 Impact factor: 8.606
Authors: Xiang Yi; Dongfen Yuan; Susan A Farr; William A Banks; Chi-Duen Poon; Alexander V Kabanov Journal: J Control Release Date: 2014-06-02 Impact factor: 9.776
Authors: John R Speakman; David A Levitsky; David B Allison; Molly S Bray; John M de Castro; Deborah J Clegg; John C Clapham; Abdul G Dulloo; Laurence Gruer; Sally Haw; Johannes Hebebrand; Marion M Hetherington; Susanne Higgs; Susan A Jebb; Ruth J F Loos; Simon Luckman; Amy Luke; Vidya Mohammed-Ali; Stephen O'Rahilly; Mark Pereira; Louis Perusse; Tom N Robinson; Barbara Rolls; Michael E Symonds; Margriet S Westerterp-Plantenga Journal: Dis Model Mech Date: 2011-11 Impact factor: 5.758
Authors: Caroline E Boeke; Christos S Mantzoros; Michael D Hughes; Sheryl L Rifas-Shiman; Eduardo Villamor; Chloe A Zera; Matthew W Gillman Journal: Obesity (Silver Spring) Date: 2013-05-25 Impact factor: 5.002